Skip to content

Establish a detection protocol for peripheral blood MDSC and study its clinical value in the diagnosis and treatment of solid tumors

Establish a detection protocol for peripheral blood MDSC and study its clinical value in the diagnosis and treatment of solid tumors

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500114749
Enrollment
Unknown
Registered
2025-12-17
Start date
2024-11-10
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid tumor

Interventions

Good prognosis:N/A
Poor prognosis:N/A
Healthy control group:N/A

Sponsors

Cancer Hospital Chinese Academy of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Healthy individuals: 18-80 years old individuals with normal blood routine, urine routine, liver function biochemical indicators, renal function biochemical indicators, and myocardial enzyme biochemical indicators. 2.Tumor patients: pathologically confirmed, untreated patients at first visit.

Exclusion criteria

Exclusion criteria: 1.Healthy individuals: individuals who had used immune-related drugs within 6 months, had autoimmune diseases, tumors or abnormal tumor markers, and abnormal electrolyte biochemical indexes. 2.Cancer patients: patients with autoimmune diseases or more than two types of cancer.

Design outcomes

Primary

MeasureTime frame
MDSC;Overall survival;

Secondary

MeasureTime frame
Progression-free survival;Cytokine Levels;Fine typing of circulating immune cells;

Countries

China

Contacts

Public ContactLin Xiao

Cancer Hospital Chinese Academy of Medical Sciences

xiaolin5022@sina.com+86 10 8778 7503

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026